Overall Survival

Researchers Tried to Determine Which Second Line Treatment is Best for Mesothelioma

Researchers from China tried to determine whether immunotherapy or chemotherapy is better as a second line treatment option for relapsed pleural mesothelioma. There is no current standard therapy for people whose mesothelioma comes back, which makes it hard for doctors to make treatment decisions for patients. Mesothelioma is very aggressive,[…]

Read More »

YAP/TEAD Inhibitor is Showing Promising Results for Mesothelioma and NF2-Mutant Cancers

A YAP/TEAD inhibitor is showing promising results for people with mesothelioma and other cancers. The inhibitor, known as VT3989, was well tolerated and had good anti-tumor effects in cancer patients with mesothelioma and NF2 mutations. Results were recently published from the first human study. Seven of 69 patients had radiological[…]

Read More »

Impact on Survival When People Have a Second Cancer in Addition to Mesothelioma

Researchers decided to look at the relationship between having mesothelioma in addition to a second cancer and their impact on survival. Researchers found that a second cancer did not affect survival for most patients with mesothelioma, but for patients with a specific type of mesothelioma, survival was affected. Mesothelioma is[…]

Read More »

Cytoreductive Surgery and Chemotherapy Improved for Mesothelioma

Improvements have been made for cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC). This treatment combination is typically performed on people with cancers in the abdominal region. One such cancer is peritoneal mesothelioma. Peritoneal mesothelioma is a cancer of the lining of the abdomen caused by asbestos exposure. Peritoneal mesothelioma is[…]

Read More »

Accelerated Hypofractionated Radiotherapy for Mesothelioma

A recent study from Italy found that accelerated hypofractionated radiotherapy could be an effective treatment for mesothelioma. This is good news for people suffering from the rare and aggressive cancer. The patients in the study had higher chances of living longer while also having a lower risk of the disease[…]

Read More »

A Vaccine to Prevent and Treat Mesothelioma Could be Possible in the Future

A vaccine for lung cancer could possibly lead to a vaccine for mesothelioma. The lung cancer immunotherapy drug CIMAvax-EFG is making great progress, and because of this progress, researchers are utilizing the treatment in new ways. The researchers are trying to see how the vaccine can be used to prevent[…]

Read More »

Gene Suppressor Therapy Could Improve Survival for Mesothelioma Patients

New mesothelioma research is being performed at The Netherlands Cancer Institute. The researchers are looking at new combinations of medications to be used on patients that have mesothelioma with BAP1 genetic mutations. More than half of patients with mesothelioma have changes in the BAP1 tumor suppressor gene. When the BAP1[…]

Read More »

Cytokine Factories to Treat Pleural and Peritoneal Mesothelioma

A new study from Rice University in Houston is showing promising results for mesothelioma. It utilizes the immune system to fight cancer cells. The protein that is being studied is interleukin 2 (IL2), which is a protein that regulates white blood cells through the use of cytokines, a cell signal[…]

Read More »

Opdivo and Yervoy After Mesothelioma Surgery Improves Survival

There might be more options for treating mesothelioma. A study looked at the combination of Opdivo and Yervoy after surgery. The study was performed at the Hyogo College of Medicine in Japan. Opdivo and Yervoy, which were recently approved for the treatment of mesothelioma, improved survival when administered after surgery.[…]

Read More »

Pleurectomy and Decortication is the Best Option for Bicavity Surgery on Peritoneal Mesothelioma

Patients with thoracic and abdominal mesothelioma can extend survival when they are given aggressive surgery. This news came from a study at Baylor College of Medicine in Houston. When patients are given bicavity cytoreductive surgery, they had a median survival of 58.2 months.  The results were published in December in[…]

Read More »